ZnT8 Monoclonal Antibodies for Inhibition and Cellular Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research lacks specific and high-affinity monoclonal antibodies to target the pancreatic zinc transporter, ZnT8, necessary for inhibiting its activity and measuring cellular levels, which is crucial for addressing type 2 diabetes management.
Innovation Solution
Development of monoclonal antibodies with sub-nanomolar affinities and selectivity for human ZnT8, capable of forming ternary complexes with ZnT8 and inhibiting zinc transport, allowing for quantification of cellular ZnT8 levels using HTRF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are developed to inhibit ZnT8 activity and measure cellular levels, then therapeutic and diagnostic capabilities are improved, but the complexity of the research tool development increases
Solution Approach 1:
The patent develops multiple monoclonal antibodies (mAb20, mAb39, Fab20, Fab39) that target different epitopes on ZnT8, segmenting the therapeutic and diagnostic functions into specialized reagents. Each antibody has specific binding characteristics that enable distinct applications in ZnT8 inhibition and quantification
Solution Approach 2:
The patent uses antibody-Fc fusion proteins and fluorescently labeled antibodies as intermediaries to measure cellular ZnT8 levels. These intermediary molecules bridge the gap between ZnT8 detection and quantification, enabling HTRF assay development without directly measuring ZnT8 itself
2Measurement precision
If high-affinity monoclonal antibodies are developed for ZnT8, then measurement precision of cellular ZnT8 levels is improved, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent employs homogeneous time resolved fluorescence (HTRF) technology that changes the measurement parameters from traditional fluorescence to time-resolved fluorescence with specific donor-acceptor pairs. This parameter change enables precise measurement of ZnT8 levels by measuring energy transfer between europium-cryptate donors and D2 or D3 acceptors
Solution Approach 2:
The patent replaces traditional mechanical or chemical measurement methods with optical field-based HTRF detection. The use of fluorescently labeled antibodies and energy transfer measurements substitutes complex biochemical assays with optical detection, improving measurement precision while simplifying the detection process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit ZnT8-mediated zinc transport and provide a means to quantify cellular ZnT8 levels, offering potential therapeutic and diagnostic tools for type 2 diabetes management.
Implementation Method 1
The mAbs exhibit sub-nanomolar affinities for human ZnT8 and selectivities against homologous zinc transporters with distinct cross-species reactivities and epitope recognition
Implementation Method 2
The co-binding of two mAbs to a single ZnT8 protein multiplied individual anti-ZnT8 specificities, allowing for quantification of the cellular ZnT8 level by homogeneous time resolved fluorescence (HTRF)
Data Source
Figure 1A~2
Figure 3A~3D
Figure 3E~3F
AI summary
The present invention relates to the fields of immunology and autoimmunity. More specifically, the present invention provides methods and compositions directed to the generation and use of antibodies to the pancreatic zinc transporter, ZnT8. The present invention also provides an isolated antibody or antigen-binding fragment thereof that specifically binds ZnT8 comprising a VH comprising one of the amino acid sequences set forth in SEQ ID NOS:2, 12, 22, 32, 42 and 52. In alternative embodiments an isolated antibody or antigen-binding fragment thereof that specifically binds ZnT8 comprises a VL comprising one of the amino acid sequences as set forth in SEQ ID NOS:7, 17, 27, 37, 47 and 57.